Citable filing context
COO's research view summarizes recent SEC filing context, starting with earnings from Sep 9, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 9, 2026 | earnings | CooperCompanies reported fiscal third quarter 2026 revenue of $1.066 billion and increased its share repurchase authorization to $3 billion. |
| Jun 4, 2026 | earnings | Cooper Companies reported Q2 2026 revenue of $1.082 billion and a $271.6 million litigation-related charge. |
| May 4, 2026 | management_change | The Cooper Companies, Inc. appointed Paul Keel to its Board of Directors, effective July 1, 2026. |
| Sep 9, 2026 | Guidance: coopersurgical_revenue | 1401.00 to 1410.00 |
| Sep 9, 2026 | Guidance: coopersurgical_revenue | 364.00 to 374.00 |
| Sep 9, 2026 | Guidance: coopervision_revenue | 692.00 to 706.00 |
| Sep 9, 2026 | mda_quarterly | The Cooper Companies reported stable net sales for the third quarter of fiscal 2026, with growth in the CooperVision segment’s toric and multifocal lenses—driven by the MyDay franchise—offsetting declines in legacy hydrogel products and softness in the Asia Pacific market, particularly Japan and China. CooperSurgical saw 2% growth, bolstered by increased surgical product sales and genetic testing revenue. Consolidated gross margins improved to 67%, benefiting from the absence of prior-year product line exit costs. A significant financial development was the $272 million net litigation expense related to the CooperSurgical embryo culture media recall. While this impacted operating income, the company successfully resolved substantially all claims via a settlement paid in August 2026. Additionally, a favorable tax authority resolution regarding a 2020 UK intellectual property transfer resulted in a $307.2 million discrete income tax benefit. Liquidity remains robust, supported by $785.4 million in operating cash flow for the first nine months of 2026. The company continues to prioritize capital allocation toward share repurchases, with $1.5 billion remaining under its authorization as of September 2026. Management maintains a positive long-term outlook despite ongoing risks, including global macroeconomic instability, foreign exchange volatility, and potential supply chain disruptions for silicone hydrogel components. |
| Jun 5, 2026 | mda_quarterly | CooperVision net sales grew 8% for the first six months of fiscal 2026, driven by silicone hydrogel products including MyDay and Biofinity. Growth was strongest in EMEA (16%) and the Americas (7%), though offset by softness in Japan. CooperSurgical net sales increased 8% in the second quarter, fueled by fertility consumables and genetic testing, despite declining Paragard contraceptive revenue. Consolidated gross margin remained flat at 68%. However, CooperSurgical reported a significant operating loss due to a $271.6 million litigation expense related to the LifeGlobal embryo culture media recall, involving over 1,500 claimants. Additional financial risks include a UK payroll tax dispute regarding the Sauflon Group acquisition with a potential loss of up to £71.7 million and ongoing compliance with EU Medical Devices Regulations. Working capital decreased to $495.1 million, primarily due to increased short-term debt, but the company maintains $1.38 billion in available revolving credit. The company continues to prioritize the shift toward single-use contact lens modalities and the expansion of MiSight for myopia management. Interest expenses decreased due to lower average debt balances and rates, while the company repurchased $105.6 million in common stock during the first half of the year. |
Source: SEC EDGAR filing text and events; period Sep 9, 2026; filed Sep 9, 2026.
COO company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.